- Home
- PRCT vs GLPG Comparison
PRCT vs GLPG Comparison
Compare PRCT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- GLPG
- Stock Information
- Founded
- PRCT 2009
- GLPG 1999
- Country
- PRCT United States
- GLPG Belgium
- Employees
- PRCT N/A
- GLPG N/A
- Industry
- PRCT Medical Specialities
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- PRCT Health Care
- GLPG Health Care
- Exchange
- PRCT Nasdaq
- GLPG Nasdaq
- Market Cap
- PRCT 2.2B
- GLPG 2.1B
- IPO Year
- PRCT 2021
- GLPG 2005
- Fundamental
- Price
- PRCT $40.62
- GLPG $33.16
- Analyst Decision
- PRCT Strong Buy
- GLPG Sell
- Analyst Count
- PRCT 8
- GLPG 4
- Target Price
- PRCT $73.63
- GLPG $25.33
- AVG Volume (30 Days)
- PRCT 1.3M
- GLPG 246.1K
- Earning Date
- PRCT 10-27-2025
- GLPG 10-29-2025
- Dividend Yield
- PRCT N/A
- GLPG N/A
- EPS Growth
- PRCT N/A
- GLPG N/A
- EPS
- PRCT N/A
- GLPG N/A
- Revenue
- PRCT $274,950,000.00
- GLPG $323,674,692.00
- Revenue This Year
- PRCT $48.38
- GLPG N/A
- Revenue Next Year
- PRCT $30.87
- GLPG N/A
- P/E Ratio
- PRCT N/A
- GLPG N/A
- Revenue Growth
- PRCT 55.71
- GLPG 5.43
- 52 Week Low
- PRCT $37.12
- GLPG $22.36
- 52 Week High
- PRCT $103.81
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- PRCT 42.58
- GLPG 58.75
- Support Level
- PRCT $37.18
- GLPG $30.88
- Resistance Level
- PRCT $42.43
- GLPG $33.25
- Average True Range (ATR)
- PRCT 1.62
- GLPG 0.75
- MACD
- PRCT 0.55
- GLPG -0.03
- Stochastic Oscillator
- PRCT 65.52
- GLPG 89.22
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.